SUZANO/WOODSPIN
Woodspin, the exclusive producer and distributor of wood-based SPINNOVA® fibre, has obtained Forest Stewardship Council® (FSC) Chain of Custody certification. This recognizes that wood used by Woodspin for its manufacturing can be fully traced from its origin to the final fibre product, providing its customers with the assurance of sustainable sourcing.
Woodspin is a 50/50 joint venture between Suzano, the world’s largest hardwood pulp producer, and Spinnova, an innovative Finnish materials technology company. Woodspin uses responsibly grown eucalyptus hardwood planted, harvested, and sourced by Suzano on farms in Brazil. Suzano is the world’s largest eucalyptus grower and manages 26,000 km2 of land, of which 40 percent is set aside for permanent conservation.
FSC® is renowned as the most rigorous international standard for responsible forestry. FSC® certification ensures that a forest is being managed in a way that preserves biological diversity and benefits the lives of local people and workers while ensuring it sustains economic viability.
Woodspin produces the unique, wood-based SPINNOVA® fibre without harmful chemicals or pollution. SPINNOVA® fibre has a 74 percent smaller life cycle carbon footprint and 98 percent less water consumption than conventional cotton.* The exclusive use of Suzano’s eucalyptus-based raw materials enables Woodspin to guarantee end-to-end traceability while remaining committed to zero deforestation and upholding comprehensive ethical and sustainable practices.
Jari Aittakari, Sales Director at Woodspin, said:
“Consumers and stakeholders at every stage of the textiles value chain deserve to know the origin of the products they buy, that these have been ethically produced, and that the materials used to make them have been sustainably sourced.
We recognize that the demand for supply chain transparency is increasing. This FSC® certification demonstrates to our partners – be that brands or producers – that Woodspin’s SPINNOVA® fibre is produced to the highest standard, from farm to fibre, without compromise.”
Fabian Farkas, Chief Markets Officer at FSC® International, said:
“As the forestry sector continues to push boundaries through innovation, key players are increasingly recognizing FSC® as the solution provider for responsible sourcing. Woodspin's FSC® Chain of Custody certification is such a significant milestone, paving the way for a more sustainable and scalable textile fibre production and ultimately a fossil fuel-free world.”
This certification follows the 2023 opening of Woodspin’s first facility producing wood-based SPINNOVA® fibre in Jyväskylä, Finland. This plant produces biodegradable textile fibres, enabling garments with hand feel close to the natural fibres made responsively from trees. Woodspin’s modern facility uses Spinnova’s fibre technology, which is designed to produce zero waste. It uses an advanced energy recovery system to recycle its only by-product – surplus heat – which can be reused in a local heating network.
The wood-based SPINNOVA® fibre is already being used by global fashion brands such as adidas and Bestseller.
About Woodspin
Woodspin is the exclusive producer and seller of wood-based SPINNOVA® fibre, a sustainable, recyclable, material made from trees. Woodspin is a 50/50 joint venture between the world’s largest hardwood pulp producer, Suzano, and Spinnova, an innovative Finnish materials technology company. Woodspin’s unique product fuses the responsibly-grown eucalyptus hardwood of Suzano with the pioneering technology of Spinnova. In our process we use radically less water and fewer CO2 emissions than alternative fibres, requiring no harmful chemicals, and leaving no waste by-products. http://woodspin.com/
About FSC ®
FSC® is a non-profit organization that provides a proven sustainable forest management solution. Currently, over 150 million hectares of forest worldwide is certified according to FSC® standards. It is widely regarded as the most rigorous forest certification system among NGOs, consumers, and businesses alike to tackle today’s deforestation, climate, and biodiversity challenges. The FSC® forest management standard is based on ten core principles designed to address a broad range of environmental, social and economic factors. FSC’s “check tree” label is found on millions of forest-based products and verifies that they are sustainably sourced, from forest to consumer. www.fsc.org.
About SPINNOVA – Sustainable textile materials, naturally
Spinnova transforms the way textiles are manufactured globally. Based in Finland, Spinnova has developed breakthrough patented technology for making textile fibre out of wood or waste, such as leather, textile or agricultural waste, without harmful chemicals. The SPINNOVA® fibre creates zero waste, and its CO2 emissions and water consumption are minimal. SPINNOVA® fibre is biodegradable and recyclable.
Spinnova is committed to using only sustainable raw materials such as FSC certified wood and waste. SPINNOVA® fibre is produced without harmful or complex chemical processes, and has the touch and feel of natural fibres such as cotton and linen. Spinnova has received awards from Fast Company, ISPO, Scandinavian Outdoor, ANDAM, Monocle and Marie Claire UK.
Spinnova’s shares (SPINN) are listed on the Nasdaq First North Growth Market Finland.
SPINNOVA® home: www.spinnova.com
Corporate & IR site: www.spinnovagroup.com
About Suzano
Suzano is the world’s largest producer of market pulp. Our responsibly grown raw materials are used in products reaching over two billion people in more than 100 countries, including tissue and toilet paper, books, printing and writing paper, diapers and period products, packaging, textiles, and a range of innovative applications that can replace products made from fossil fuels.
Our pulp is made using biomass produced from farmed eucalyptus trees, offering a biodegradable, renewable and recyclable raw material for consumer and industrial use. We plant 1.2 million trees a day and only harvest what we plant. We manage around 26,000 km2 of land and around 40% of this is protected for permanent conservation, with a zero deforestation policy across all of our operations.
Suzano’s history goes back over 100 years. We are listed on the B3 stock exchange in Brazil (SUZB3) and the NYSE (SUZ) in the United States. Learn more at: www.suzano.com.br/en.
Disclaimer
*CO2e emission comparison is based on a projected product carbon footprint conducted by a third-party expert following the ISO 14067:2018 standard. Ecoinvent database has been used as the source for global average CO2e emissions of conventional cotton. Water consumption comparison is based on a projected, screening Life Cycle Assessment (LCA) conducted by a third-party expert. Both comparisons include raw material supply, transportation of raw materials, and manufacturing of the product (cradle-to-gate).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240510834910/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
